[1] WILLIAM M. MOORE. L-N6-(1-Iminoethyl)lysine: A Selective Inhibitor of Inducible Nitric Oxide Synthase[J]. Journal of Medicinal Chemistry, 1994, 37 23: 3886-3888. DOI:
10.1021/jm00049a007[2] STEPHAN K. GRANT. Structural Requirements for Human Inducible Nitric Oxide Synthase Substrates and Substrate Analogue Inhibitors[J]. Biochemistry Biochemistry, 1998, 37 12: 4174-4180. DOI:
10.1021/bi972481d[3] STEFFEN STENGER . l-N6-(1-Iminoethyl)-lysine potently inhibits inducible nitric oxide synthase and is superior to NG-monomethyl-arginine in vitro and in vivo[J]. European journal of pharmacology, 1995, 294 2: Pages 703-712. DOI:
10.1016/0014-2999(95)00618-4[4] M. BUDZINSKI. Inhibition of inducible nitric oxide synthase in persistent pain[J]. Life sciences, 1999, 66 4: Pages 301-305. DOI:
10.1016/s0024-3205(99)00421-x[5] W S FARACI. 2-Amino-4-methylpyridine as a potent inhibitor of inducible NO synthase activity in vitro and in vivo.[J]. British Journal of Pharmacology, 1996, 119 6: 1101-1108. DOI:
10.1111/j.1476-5381.1996.tb16010.x[6] A DIEFENBACH. Type 1 interferon (IFNalpha/beta) and type 2 nitric oxide synthase regulate the innate immune response to a protozoan parasite.[J]. Immunity, 1998, 8 1: 77-87. DOI:
10.1016/s1074-7613(00)80460-4